Management of Hepatitis C in Patients with Chronic Kidney Disease

Overview

Journal Curr Gastroenterol Rep

Specialty Gastroenterology

Date 2011 Dec 14

PMID 22161023

Citations 4

Authors

Mohammad A B Al-Freah

Zeino Zeino

Michael A Heneghan

Affiliations

Soon will be listed here.

Abstract

Chronic kidney disease represents a global health problem. Chronic hepatitis C virus (HCV) infection is prevalent in patients with end stage renal disease (ESRD) on hemodialysis (HD) and in renal transplant recipients with significant impact on morbidity and mortality. Furthermore, HCV can cause various forms of glomerulopathy with the predominant type being cryglobulinemia associated membranoproliferative glomerulonephritis. Liver enzymes are traditionally used as markers of liver injury; however, there is wide variation in aminotransferase levels in patients with ESRD. Therefore, diagnosis of chronic hepatitis C (CHC) in patients with ESRD is based on HCV antibody testing and further confirmation with polymerase chain reaction testing. Current standard therapy for CHC is composed of pegylated interferon and ribavirin. However, this combination is challenging in patients with ESRD due to its tolerability. We describe in this review relevant issues in epidemiology, diagnosis and management of CHC in ESRD, HD and renal transplant recipients.

Citing Articles

Chronic Kidney Disease, Spirituality and Religiosity: A Systematic Overview with the List of Eligible Studies.

Bragazzi N, Del Puente G Health Psychol Res. 2016; 1(2):e26.

PMID: 26973911 PMC: 4768585. DOI: 10.4081/hpr.2013.e26.

Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review.

Aguirre Valadez J, Garcia Juarez I, Rincon Pedrero R, Torre A Ther Clin Risk Manag. 2015; 11:329-38.

PMID: 25767389 PMC: 4354469. DOI: 10.2147/TCRM.S74282.

Management of patients with hepatitis C infection and renal disease.

Bunchorntavakul C, Maneerattanaporn M, Chavalitdhamrong D World J Hepatol. 2015; 7(2):213-25.

PMID: 25729476 PMC: 4342603. DOI: 10.4254/wjh.v7.i2.213.

The application and mechanism of action of ribavirin in therapy of hepatitis C.

Thomas E, Ghany M, Liang T Antivir Chem Chemother. 2012; 23(1):1-12.

PMID: 22592135 PMC: 6271563. DOI: 10.3851/IMP2125.

References

Di Napoli A, Pezzotti P, Di Lallo D, Petrosillo N, Trivelloni C, Di Giulio S . Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis. 2006; 48(4):629-37. DOI: 10.1053/j.ajkd.2006.07.004. View

Sabry A, Sobh M, Sheaashaa H, Kudesia G, Wild G, Fox S . Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol Dial Transplant. 2002; 17(11):1924-30. DOI: 10.1093/ndt/17.11.1924. View

Jacobson I, McHutchison J, Dusheiko G, Di Bisceglie A, Reddy K, Bzowej N . Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25):2405-16. DOI: 10.1056/NEJMoa1012912. View

Gane E, Pilmore H . Management of chronic viral hepatitis before and after renal transplantation. Transplantation. 2002; 74(4):427-37. DOI: 10.1097/00007890-200208270-00001. View

Souza J, Longui C, Miorin L, Sens Y . Gamma-glutamyltransferase activity in chronic dialysis patients and renal transplant recipients with hepatitis C virus infection. Transplant Proc. 2008; 40(5):1319-23. DOI: 10.1016/j.transproceed.2008.03.157. View

Saadoun D, Resche-Rigon M, Sene D, Perard L, Karras A, Cacoub P . Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis. 2008; 67(10):1431-6. DOI: 10.1136/ard.2007.081653. View

Fabrizi F, MARTIN P, Ponticelli C . Hepatitis C virus infection and renal transplantation. Am J Kidney Dis. 2001; 38(5):919-34. DOI: 10.1053/ajkd.2001.28576. View

Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi P . Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994; 330(11):751-6. DOI: 10.1056/NEJM199403173301104. View

Pereira B, Wright T, Schmid C, Bryan C, Cheung R, Cooper E . Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a U.S. National Collaborative Study. Kidney Int. 1994; 46(3):886-92. DOI: 10.1038/ki.1994.346. View

10.

van Leusen R, Adang R, de Vries R, Cnossen T, Konings C, Schalm S . Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2007; 23(2):721-5. DOI: 10.1093/ndt/gfm724. View

11.

Schmitz V, Kiessling A, Bahra M, Puhl G, Kahl A, Berg T . Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann Transplant. 2008; 12(3):22-7. View

12.

Al-Harbi A, Malik G, Subaity Y, Mansy H, Abutaleb N . Treatment of acute hepatitis C virus infection with alpha interferon in patients on hemodialysis. Saudi J Kidney Dis Transpl. 2007; 16(3):293-7. View

13.

Fabrizi F, Lunghi G, Dixit V, MARTIN P . Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther. 2006; 24(10):1413-22. DOI: 10.1111/j.1365-2036.2006.03151.x. View

14.

Schneeberger P, Keur I, van der Vliet W, Van Hoek K, Boswijk H, van Loon A . Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol. 1998; 36(6):1711-5. PMC: 104905. DOI: 10.1128/JCM.36.6.1711-1715.1998. View

15.

Glicklich D, Thung S, Kapoian T, Tellis V, Reinus J . Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant recipients. Am J Gastroenterol. 1999; 94(1):159-63. DOI: 10.1111/j.1572-0241.1999.00788.x. View

16.

Ahmed M, Wong C . Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C?. J Nephrol. 2007; 20(3):350-6. View

17.

Wills R . Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990; 19(5):390-9. DOI: 10.2165/00003088-199019050-00003. View

18.

Kirk A, Heisey D, DAlessandro A, Knechtle S, Odorico J, Rayhill S . Clinical hepatitis after transplantation of hepatitis C virus-positive kidneys: HLA-DR3 as a risk factor for the development of posttransplant hepatitis. Transplantation. 1996; 62(12):1758-62. DOI: 10.1097/00007890-199612270-00011. View

19.

Espinosa M, Martin-Malo A, Alvarez de Lara M, Gonzalez R, Rodriguez M, Aljama P . Natural history of acute HCV infection in hemodialysis patients. Clin Nephrol. 2002; 58(2):143-50. DOI: 10.5414/cnp58143. View

20.

Pereira B, Milford E, Kirkman R, Quan S, Sayre K, Johnson P . Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med. 1992; 327(13):910-5. DOI: 10.1056/NEJM199209243271302. View